JP2018532407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532407A5 JP2018532407A5 JP2018520157A JP2018520157A JP2018532407A5 JP 2018532407 A5 JP2018532407 A5 JP 2018532407A5 JP 2018520157 A JP2018520157 A JP 2018520157A JP 2018520157 A JP2018520157 A JP 2018520157A JP 2018532407 A5 JP2018532407 A5 JP 2018532407A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- chimeric receptor
- endodomain
- receptor
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700010039 chimeric receptor Proteins 0.000 claims description 163
- 150000007523 nucleic acids Chemical group 0.000 claims description 122
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 88
- 102000003675 cytokine receptors Human genes 0.000 claims description 52
- 108010057085 cytokine receptors Proteins 0.000 claims description 52
- 230000003834 intracellular effect Effects 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 25
- 108020001507 fusion proteins Proteins 0.000 claims description 22
- 102000037865 fusion proteins Human genes 0.000 claims description 22
- 102000042286 type I cytokine receptor family Human genes 0.000 claims description 20
- 108091052247 type I cytokine receptor family Proteins 0.000 claims description 20
- 102000035160 transmembrane proteins Human genes 0.000 claims description 18
- 108091005703 transmembrane proteins Proteins 0.000 claims description 18
- 125000006850 spacer group Chemical group 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 230000005754 cellular signaling Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000004186 co-expression Effects 0.000 claims description 6
- 108020001756 ligand binding domains Proteins 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 4
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 4
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 4
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims description 4
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000000139 costimulatory effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000010276 construction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007006A JP2022058681A (ja) | 2015-10-23 | 2022-01-20 | 受容体 |
| JP2023222448A JP2024024014A (ja) | 2015-10-23 | 2023-12-28 | 受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1518816.2A GB201518816D0 (en) | 2015-10-23 | 2015-10-23 | Receptor |
| GB1518816.2 | 2015-10-23 | ||
| PCT/GB2016/053290 WO2017068360A1 (en) | 2015-10-23 | 2016-10-21 | Receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007006A Division JP2022058681A (ja) | 2015-10-23 | 2022-01-20 | 受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532407A JP2018532407A (ja) | 2018-11-08 |
| JP2018532407A5 true JP2018532407A5 (cg-RX-API-DMAC7.html) | 2019-10-03 |
| JP7082046B2 JP7082046B2 (ja) | 2022-06-07 |
Family
ID=55130152
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520157A Active JP7082046B2 (ja) | 2015-10-23 | 2016-10-21 | 受容体 |
| JP2022007006A Withdrawn JP2022058681A (ja) | 2015-10-23 | 2022-01-20 | 受容体 |
| JP2023222448A Pending JP2024024014A (ja) | 2015-10-23 | 2023-12-28 | 受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007006A Withdrawn JP2022058681A (ja) | 2015-10-23 | 2022-01-20 | 受容体 |
| JP2023222448A Pending JP2024024014A (ja) | 2015-10-23 | 2023-12-28 | 受容体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11242377B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3364998A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7082046B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108135988A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016342560B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3001792A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201518816D0 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1252163A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017068360A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US11753460B2 (en) | 2016-12-13 | 2023-09-12 | Seattle Children's Hospital | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | Car t细胞的使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| WO2019169290A1 (en) | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| EP3784259A4 (en) | 2018-04-27 | 2021-12-29 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Rapamycin resistant cells |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| US20230348556A1 (en) * | 2019-02-21 | 2023-11-02 | Arbele Limited | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same |
| JP7633937B2 (ja) | 2019-03-01 | 2025-02-20 | アロジーン セラピューティクス，インコーポレイテッド | Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体 |
| AU2020232597B2 (en) | 2019-03-01 | 2025-08-07 | Allogene Therapeutics, Inc. | Constitutively active chimeric cytokine receptors |
| EP4031583A4 (en) * | 2019-09-16 | 2023-11-15 | Fred Hutchinson Cancer Center | CHIMERIC RECEPTOR PROTEINS AND THEIR USES |
| CN115175929A (zh) | 2020-02-24 | 2022-10-11 | 艾洛基治疗公司 | 活性增强的bcma car-t细胞 |
| CN111269326A (zh) * | 2020-02-28 | 2020-06-12 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| TW202436337A (zh) | 2023-01-23 | 2024-09-16 | 漢諾威醫學院 | 嵌合抗原受體 |
| AU2024219048A1 (en) | 2023-02-07 | 2025-08-07 | Quell Therapeutics Limited | Culture method for treg cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| ES2595307T3 (es) | 2007-01-31 | 2016-12-29 | Yeda Research And Development Company Limited | Células T reguladoras redirigidas, modificadas genéticamente y su uso en la supresión de enfermedades autoinmunes e inflamatorias |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| ES2649967T3 (es) * | 2011-04-08 | 2018-01-16 | Baylor College Of Medicine | Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| KR102417657B1 (ko) * | 2013-02-06 | 2022-07-07 | 안트로제네시스 코포레이션 | 개선된 특이성을 갖는 변경된 t 림프구 |
| AU2014240083C1 (en) | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| US10174095B2 (en) * | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| SG11201700416TA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| CA2974998C (en) * | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| US11248058B2 (en) | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| MA41962A (fr) * | 2015-04-23 | 2018-02-28 | Baylor College Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
| US11154572B2 (en) | 2015-06-05 | 2021-10-26 | Board Of Regents, The University Of Texas System | Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
-
2015
- 2015-10-23 GB GBGB1518816.2A patent/GB201518816D0/en not_active Ceased
-
2016
- 2016-10-21 WO PCT/GB2016/053290 patent/WO2017068360A1/en not_active Ceased
- 2016-10-21 HK HK18111556.3A patent/HK1252163A1/zh unknown
- 2016-10-21 AU AU2016342560A patent/AU2016342560B2/en not_active Expired - Fee Related
- 2016-10-21 US US15/770,110 patent/US11242377B2/en active Active
- 2016-10-21 CA CA3001792A patent/CA3001792A1/en not_active Abandoned
- 2016-10-21 EP EP16787536.8A patent/EP3364998A1/en active Pending
- 2016-10-21 CN CN201680061278.7A patent/CN108135988A/zh active Pending
- 2016-10-21 JP JP2018520157A patent/JP7082046B2/ja active Active
-
2021
- 2021-12-22 US US17/560,022 patent/US20220275052A1/en active Pending
-
2022
- 2022-01-20 JP JP2022007006A patent/JP2022058681A/ja not_active Withdrawn
-
2023
- 2023-12-28 JP JP2023222448A patent/JP2024024014A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532407A5 (cg-RX-API-DMAC7.html) | ||
| AU2018203687B2 (en) | Improved methods for manufacturing adoptive cell therapies | |
| RU2719030C2 (ru) | Улучшенные композиции на основе t-клеток | |
| JP2022173235A (ja) | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 | |
| US11999773B2 (en) | Anti-BCMA chimeric antigen receptors | |
| JP2016538855A5 (cg-RX-API-DMAC7.html) | ||
| RU2016124280A (ru) | Клетка | |
| JP2019150066A5 (cg-RX-API-DMAC7.html) | ||
| RU2017121892A (ru) | Клетка | |
| JP2018523484A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537627A5 (cg-RX-API-DMAC7.html) | ||
| JP2020513754A5 (cg-RX-API-DMAC7.html) | ||
| CN107106670A (zh) | 用于修饰的t细胞的方法和组合物 | |
| JP2016514462A5 (cg-RX-API-DMAC7.html) | ||
| JP2021517473A (ja) | Ｃｄ３０＋腫瘍の治療のためのｃａｒ−ｃｄ３０ｔ細胞 | |
| JP2019535262A5 (cg-RX-API-DMAC7.html) | ||
| JP2024023497A (ja) | ＴＧＦ－β受容体及び使用方法 |